AngioDynamics, Inc. (ANGO)

NASDAQ: ANGO · Real-Time Price · USD
8.89
+0.31 (3.61%)
Dec 20, 2024, 4:00 PM EST - Market closed
3.61%
Market Cap 361.24M
Revenue (ttm) 292.73M
Net Income (ttm) -243.03M
Shares Out 40.63M
EPS (ttm) -6.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 541,524
Open 8.52
Previous Close 8.58
Day's Range 8.52 - 8.96
52-Week Range 5.26 - 9.58
Beta 0.67
Analysts Strong Buy
Price Target 12.00 (+34.98%)
Earnings Date Jan 8, 2025

About ANGO

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergen... [Read more]

Sector Healthcare
IPO Date May 27, 2004
Employees 748
Stock Exchange NASDAQ
Ticker Symbol ANGO
Full Company Profile

Financial Performance

In 2024, AngioDynamics's revenue was $303.91 million, a decrease of -10.28% compared to the previous year's $338.75 million. Losses were -$184.35 million, 251.5% more than in 2023.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ANGO stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 34.98% from the latest price.

Price Target
$12.0
(34.98% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

2 days ago - Business Wire

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

12 days ago - Business Wire

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

2 months ago - Business Wire

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

2 months ago - Business Wire

AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript

AngioDynamics, Inc. (NASDAQ:ANGO) Q1 2025 Earnings Conference Call October 3, 2024 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vic...

2 months ago - Seeking Alpha

AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday

U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday.

Other symbols: LEVINGVT
2 months ago - Benzinga

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

2 months ago - Business Wire

Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings

AngioDynamics, Inc. ANGO will release earnings results for its first quarter, before the opening bell on Thursday, Oct. 3.

2 months ago - Benzinga

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

3 months ago - Business Wire

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

3 months ago - Business Wire

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

3 months ago - Business Wire

AngioDynamics to Participate in Upcoming Investor Conferences

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

5 months ago - Business Wire

AngioDynamics: Lumpy Progress Is Still Progress

AngioDynamics stock reacted positively to fiscal Q4 results, up over 25% in a day, as the company saw 8% sequential revenue growth and 14% growth from the Med Tech portfolio. Auryon and NanoKnife gene...

5 months ago - Seeking Alpha

Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance

Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16.

5 months ago - Benzinga

AngioDynamics (ANGO) Q4 2024 Earnings Call Transcript

AngioDynamics Inc. (NASDAQ:ANGO) Q4 2024 Earnings Conference Call July 16, 2024 8:00 AM ET Company Participants Jim Clemmer - President & CEO Stephen Trowbridge - EVP & CFO Conference Call Participan...

5 months ago - Seeking Alpha

AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

5 months ago - Business Wire

AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

5 months ago - Business Wire

AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

7 months ago - Business Wire

AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

8 months ago - Business Wire

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. The recent approval of the AlphaV...

9 months ago - Seeking Alpha

AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript

AngioDynamics Inc. (NASDAQ:ANGO) Q3 2024 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants Jim Clemmer - President, Chief Executive Officer Steve Trowbridge - Executive Vice Pres...

9 months ago - Seeking Alpha

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on Febru...

9 months ago - Business Wire

AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

9 months ago - Business Wire

AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

9 months ago - Business Wire

AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

9 months ago - Business Wire